Kala Bio signs LOI to buy nationwide telehealth platform for about $15 million

• Kala Bio signed a non-binding LOI to buy a privately held MSO supporting a 50-state telehealth platform.
• Transaction valued at about 15 million, payable in cash and Kala stock; cash portion expected from existing balance sheet resources.
• Target posted USD 12.7 million trailing-12-month revenue ended August 2026; management described the business as cash-flow positive.
• Platform has served more than 90,000 clients since 2023; more than USD 48 million in sales since inception.
• Due diligence set for 45 days, expected to end in November 2026; closing targeted for late 2026 or early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609290730NEWSFILECNPR____20260929_316479_1) on September 29, 2026, and is solely responsible for the information contained therein.